Susquehanna International Group’s Tonix Pharmaceuticals TNXP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.03M Buy
75,100
+39,800
+113% +$613K ﹤0.01% 7810
2025
Q4
$551K Buy
35,300
+21,100
+149% +$389K ﹤0.01% 8543
2025
Q3
$343K Buy
+14,200
New +$527K ﹤0.01% 9805
2017
Q2
Hold
0
-$62K 9848
2017
Q1
Hold
0
8544
2016
Q3
Hold
0
-$25K 9058
2016
Q2
Hold
0
8356
2016
Q1
Hold
0
-$607K 9673
2015
Q4
Hold
0
6397
2015
Q3
Hold
0
8725
2015
Q2
Hold
0
9445
2014
Q4
Hold
0
-$271K 10103
2014
Q3
Hold
0
8176

Other funds holding TNXP

Susquehanna International Group's TNXP Position: Q1 2026 in Review

Susquehanna International Group reduced its Tonix Pharmaceuticals (TNXP) stake by 0.28% in Q1 2026, selling an estimated $1.28K and leaving 29,579 shares worth $407K. The position accounts for ﹤0.01% of the portfolio, ranked #10166.

Susquehanna International Group first reported a position in TNXP in Q1 2021 and has held it in 5 quarters since. The position peaked at $1.01M in Q1 2021. 81 funds tracked by Wall St. Rank hold TNXP as of Q1 2026.

  • Susquehanna International Group held 29,579 shares of Tonix Pharmaceuticals worth $407K as of Q1 2026.
  • Susquehanna International Group sold 83 Tonix Pharmaceuticals shares in Q1 2026, an estimated $1.28K.
  • Tonix Pharmaceuticals made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #10166 holding.
  • Susquehanna International Group first reported a position in Tonix Pharmaceuticals in Q1 2021 and has held it in 5 quarters since.
  • Susquehanna International Group's Tonix Pharmaceuticals position peaked at $1.01M in Q1 2021.
  • 81 funds tracked by Wall St. Rank held Tonix Pharmaceuticals as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.